SpayVac for Wildlife, along with BioVaxys Technology Corp, has completed the setup of its new research and production facility to produce long-lasting, single-dose veterinary contraceptive vaccines, the company announced today.

“I’m enthusiastic about the many benefits of this space,” SpayVac for Wildlife CEO Tom Do’Orazio said in a statement. “It is flexible enough for us to do both our research and small-scale production. The Lytic facility has a number of other biopharma tenant companies, such as Kendrick Laboratories and Plumb Pharmaceuticals, creating a biotech hub and collaborative environment.”

According to a release, SpayVac for Wildlife, with support from the BrightStar Wisconsin Foundation and angel investors, was able to expand its laboratory and lease space in a building owned by Lytic Solutions.

As previously reported, the company is planning to commercialize soon fertility control vaccines for deer, horses and other animals that are also based on the patented liposome-based delivery-platform technology licensed from BioVaxys.